Optime Care president and CEO Donovan Quill’s byline featured in April issue of Pharmacy Times (pages 33-36):
A growing understanding of genetics and genomics and how they drive health, disease management and drug responses in each patient is enabling doctors to provide better disease prevention, more accurate diagnoses, safer drug prescriptions and more effective treatments for many diseases. Personalized medicine (PM) tailors care to each person’s unique genetic makeup, which can improve outcomes and lower costs.
For device and drug manufacturers, PM provides an opportunity to develop agents targeted for specific patient groups that don’t respond to medications. But effective PM requires changes in practice patterns and management strategies for health care practitioners, as well as for manufacturers in reimbursement, regulatory practices and knowledge sharing. What’s more, barriers to implementation must be overcome to effectively harness the ability to individualize diagnoses and prognoses.
By taking a patient-first approach to PM, drug manufacturers can help to optimize patient care and gain a stronger financial foothold.
